TRAIL receptor 2 agonists - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “TRAIL receptor 2 agonists - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL receptor 2 agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
TRAIL receptor 2 agonists: Overview
TRAIL receptor 2 (TRAILR2), also known as Death receptor 5 (DR5), is a cell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) preferentially induces apoptosis in neoplastic cells upon binding to its receptors TRAIL-R1 and TRAIL-R2. This biological principle has been adopted for the development of cancer-selective therapies. However, many tumor cells are resistant to TRAIL and moreover TRAIL-R1/R2 can activate pro-inflammatory pathways thereby promoting invasion, migration, and metastasis
Report Highlights
This segment of the TRAIL receptor 2 agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TRAIL receptor 2 agonists Emerging Drugs
Further product details are provided in the report……..
TRAIL receptor 2 agonists: Therapeutic Assessment
This segment of the report provides insights about the different TRAIL receptor 2 agonists drugs segregated based on following parameters that define the scope of the report, such as:
TRAIL receptor 2 agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TRAIL receptor 2 agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TRAIL receptor 2 agonists drugs.
TRAIL receptor 2 agonists Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “TRAIL receptor 2 agonists - Pipeline Insight, 2022” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in TRAIL receptor 2 agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
TRAIL receptor 2 agonists: Overview
TRAIL receptor 2 (TRAILR2), also known as Death receptor 5 (DR5), is a cell surface receptor of the TNF-receptor superfamily that binds TRAIL and mediates apoptosis. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) preferentially induces apoptosis in neoplastic cells upon binding to its receptors TRAIL-R1 and TRAIL-R2. This biological principle has been adopted for the development of cancer-selective therapies. However, many tumor cells are resistant to TRAIL and moreover TRAIL-R1/R2 can activate pro-inflammatory pathways thereby promoting invasion, migration, and metastasis
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence TRAIL receptor 2 agonists R&D. The therapies under development are focused on novel approaches for TRAIL receptor 2 agonists.
This segment of the TRAIL receptor 2 agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TRAIL receptor 2 agonists Emerging Drugs
- INBRX-109: Inhibrx
- BI 905711: Travere Therapeutics
Further product details are provided in the report……..
TRAIL receptor 2 agonists: Therapeutic Assessment
This segment of the report provides insights about the different TRAIL receptor 2 agonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on TRAIL receptor 2 agonists
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
TRAIL receptor 2 agonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TRAIL receptor 2 agonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TRAIL receptor 2 agonists drugs.
TRAIL receptor 2 agonists Report Insights
- TRAIL receptor 2 agonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing TRAIL receptor 2 agonists drugs?
- How many TRAIL receptor 2 agonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of TRAIL receptor 2 agonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TRAIL receptor 2 agonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TRAIL receptor 2 agonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Inhibrx
- Boehringer Ingelheim
- IGM Biosciences
- Amgen
- Genmab
- Theraly Fibrosis
- IGM Biosciences
- INBRX-109
- BI 905711
- IGM 8444
- Conatumumab
- Benufutamab
- TLY 012
- Anti-DR5 IgM antibody
Introduction
Executive Summary
TRAIL receptor 2 agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TRAIL receptor 2 agonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
INBRX-109: Inhibrx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BI 905711: Boehringer Ingelheim
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
TLY 012: Theraly Fibrosis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TRAIL receptor 2 agonists Key Companies
TRAIL receptor 2 agonists Key Products
TRAIL receptor 2 agonists- Unmet Needs
TRAIL receptor 2 agonists- Market Drivers and Barriers
TRAIL receptor 2 agonists- Future Perspectives and Conclusion
TRAIL receptor 2 agonists Analyst Views
TRAIL receptor 2 agonists Key Companies
Appendix
Executive Summary
TRAIL receptor 2 agonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
TRAIL receptor 2 agonists – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
INBRX-109: Inhibrx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
BI 905711: Boehringer Ingelheim
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
TLY 012: Theraly Fibrosis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TRAIL receptor 2 agonists Key Companies
TRAIL receptor 2 agonists Key Products
TRAIL receptor 2 agonists- Unmet Needs
TRAIL receptor 2 agonists- Market Drivers and Barriers
TRAIL receptor 2 agonists- Future Perspectives and Conclusion
TRAIL receptor 2 agonists Analyst Views
TRAIL receptor 2 agonists Key Companies
Appendix